Prot #NU HM16B03: Neoadjuvant Phase II Study of Everolimus Plus Cisplatin in Triple Negative Breast Cancer Patients with Residual Disease After Standard Chemotherapy

Project: Research project

Project Details

StatusFinished
Effective start/end date3/30/173/30/20

Funding

  • Methodist Hospital Research Institute (Prot #NU HM16B03)
  • Novartis Pharmaceuticals Corporation (Prot #NU HM16B03)